LearnDrugs.com
Immune / Anti-infective

Systemic Antifungals

High-yield Verified · Jul 2026

Prototype: fluconazole

The systemic counterparts to the topical antifungals — for invasive fungal disease, with much more serious toxicity.

How it works in the body

The system involved, what goes wrong, and how the drug and body interact.

01 The target — the fungal membrane and wall

Fungal cells are protected by a membrane built around ergosterol (the fungal equivalent of the cholesterol in human membranes) and a cell wall made of glucan. Systemic antifungals attack these fungal-specific structures. Because human cells use cholesterol, not ergosterol, targeting ergosterol gives selectivity — but it isn’t perfect, which is why systemic antifungals are more toxic than antibiotics.

Three classes matter: azoles (fluconazole, voriconazole — the workhorses), polyenes (amphotericin B — the heavy hitter), and echinocandins (the `-fungin` drugs — the best tolerated).

Azoles block ergosterol synthesis; amphotericin binds ergosterol (pores); echinocandins block the cell wall.

02 Amphotericin B — effective but "ampho-terrible"

Amphotericin B is the broad, potent drug reserved for severe/life-threatening fungal infections — and it is notoriously toxic, nicknamed "ampho-terrible." Two toxicities dominate: infusion reactions (fever, chills/rigors, nausea — often premedicated with acetaminophen, antihistamine, ± meperidine for rigors) and nephrotoxicity with potassium and magnesium wasting (hypokalemia/hypomagnesemia). Slow infusion, hydration, electrolyte repletion, and lipid formulations (less nephrotoxic) reduce the harm.

The azoles are far better tolerated but are CYP450 inhibitors — a major source of drug interactions (raising levels of statins, warfarin, and many others) — and can be hepatotoxic and prolong the QT. Echinocandins (`-fungin`) are IV and the best tolerated, used especially for invasive Candida.

Amphotericin B’s two signature toxicities: infusion reactions and nephrotoxicity + electrolyte wasting.

Drug names

Generic Brand
fluconazole Diflucan
voriconazole Vfend
amphotericin B —
caspofungin Cancidas

Indications

  • Invasive/systemic fungal infections (candidemia, aspergillosis, cryptococcal meningitis, endemic mycoses)
  • Serious mucosal candidiasis; antifungal prophylaxis in immunocompromised patients
  • Amphotericin B for severe/refractory disease; echinocandins for invasive Candida

Mechanism of action

Azoles inhibit ergosterol synthesis (CYP-dependent 14-α-demethylase), disrupting the fungal membrane. Amphotericin B binds ergosterol, forming membrane pores that leak cell contents. Echinocandins inhibit β-(1,3)-glucan synthase, weakening the cell wall.

In plain terms
They break down the fungus’s membrane or wall — either by blocking its building block (azoles), poking holes (amphotericin), or wrecking its wall (echinocandins).

Therapeutic effects — what you'll see working

Success is clearing an invasive fungal infection. The nursing focus is amphotericin’s infusion/renal toxicity and the azoles’ drug interactions and liver/QT effects.

Fungicidal/fungistatic effect
Fungicidal/fungistatic effect
Disrupting the fungal membrane or wall clears invasive infection over the treatment course.

Adverse effects

The profile depends on the class: amphotericin (infusion + renal/electrolyte), azoles (interactions, liver, QT), echinocandins (well tolerated).

Caution: Common
Azoles: GI upset, headache, rash. Amphotericin: infusion-related fever/chills/rigors, phlebitis. Echinocandins: generally well tolerated.
Amphotericin’s infusion reactions are managed with premedication and slower infusion; azole GI/rash effects are usually mild.
Warning: Serious Hold & notify
Amphotericin: nephrotoxicity, hypokalemia/hypomagnesemia. Azoles: hepatotoxicity, QT prolongation, major CYP450 drug interactions; voriconazole visual disturbances.
Amphotericin nephrotoxicity with electrolyte wasting requires renal/electrolyte monitoring, hydration, and (often) lipid formulations. Azoles inhibit CYP450 — screen for interactions (statins, warfarin) — and can be hepatotoxic and prolong QT.

Interactions

Statins, warfarin (and other CYP3A4 substrates) drug
Azoles are CYP450 inhibitors → raise substrate levels (↑ statin myopathy, ↑ warfarin effect/INR bleeding).

Contraindications

The cautions are renal disease (amphotericin), the many azole interactions, and pregnancy/QT.

Renal impairment (amphotericin — caution/lipid formulation) use caution
Amphotericin is nephrotoxic; existing kidney disease compounds it.
Concurrent CYP3A4-dependent drugs (statins, certain benzodiazepines, warfarin) — azoles
Azole CYP inhibition raises their levels toward toxicity.
Pregnancy (azoles — high dose); QT prolongation use caution
High-dose azoles are teratogenic; several prolong the QT interval.

Labs & levels

Test Therapeutic / normal Toxic / critical
LFTs (AST/ALT) Baseline & during **azole** therapy — azoles can be **hepatotoxic** Normal range AST 10–40 · ALT 7–56 U/L —
Potassium / magnesium & renal function (SCr) During **amphotericin B** — it wastes **K⁺/Mg²⁺** and is **nephrotoxic** Normal range K⁺ 3.5–5.0 · Mg²⁺ 1.5–2.5 mEq/L · SCr 0.6–1.2 mg/dL —

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Amphotericin B care
Premedicate and infuse slowly; monitor renal function and potassium/magnesium, and hydrate.
Why: Reduces infusion reactions and nephrotoxicity; amphotericin wastes potassium and magnesium.
Azole/echinocandin care
Screen the med list for CYP450 interactions; monitor LFTs (azoles).
Why: Azoles raise levels of many drugs and can be hepatotoxic.
Teach patients to complete the (often long) course and report jaundice/vision changes.
Why: Prevents relapse; flags hepatotoxicity and voriconazole visual effects.

Sources

Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.